Skip to content
pharmaceutical daily

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • News by region
    • East and Central Asia
    • Europe
    • Latin America
    • Middle East and North Africa
    • North America
  • Pharma Business
  • My Pharmaceutical
  • About us
    • Media Kit
    • Privacy Policy
  • Contact

Tag: Xtandi

Trovagene expands the use of Onvansertib

Trovagene has expanded the use of Onvansertib to enable it for combination therapies with anti-androgen drugs, like Zytiga, Xtandi and Erledea to treat castrate-resistant prostate cancer.

Published January 23, 2019
Categorized as news Tagged abiraterone acetate, Erleada, Onvansertib, Trovagene, Xtandi, Zytiga

Pfizer/Astellas’s cancer drug study fails

Cancer study

Pfizer and Astellas Pharma  have announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with Xtandi (enzalutamide), plus abiraterone acetate and prednisone as compared to treatment with abiraterone acetate and prednisone alone.

Published December 15, 2016
Categorized as news, North America Tagged Astellas, metastatic castration-resistant prostate cancer, Pfizer, Xtandi

Astellas’s and Pfizer’s cancer drug gets new product label data

Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …

Published October 24, 2016
Categorized as Approval, news Tagged Astellas, CRPC, FDA, Pfizer, prostate cancer, Terrain, Xtandi




pharmaceutical daily
Proudly powered by WordPress.